Singapore’s Biobot Surgical raises US$15.6M to take prostate-care robot global
Summary
Singapore-based medtech company Biobot Surgical has raised SGD 20 million (about US$15.6 million) in a financing round led by ClavystBio, with participation from ZIG Ventures, as it looks to expand global adoption of its robotic-assisted prostate cancer care platform and enter the US market. The company develops Mona Lisa, a platform that combines robotic needle […] The post Singapore’s Biobot Surgical raises US$15.6M to take prostate-care robot global appeared first on e27 .
Why It Matters
This Robotics & Manufacturing development accelerates factory automation, industrial AI and precision manufacturing across the region. For Singapore, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorRobotics & Manufacturing
- MarketSingapore
- ImpactMedium (52/100)
- SignalFunding